Accessibility Menu
 
Mayne Pharma Group logo

Mayne Pharma Group

(ASX) MYX

Current Price$2.24
Market Cap$175.49M
Since IPO (2007)-70%
5 Year-74%
1 Year-68%
1 Month-15%

Mayne Pharma Group Financials at a Glance

Market Cap

$175.49M

Revenue (TTM)

$820.64M

Net Income (TTM)

$212.46M

EPS (TTM)

$-1.02

P/E Ratio

-2.11

Dividend

$0.00

Beta (Volatility)

0.03 (Low)

Price

$2.24

Volume

324,625

Open

$2.30

Previous Close

$2.24

Daily Range

$2.18 - $2.30

52-Week Range

$2.04 - $7.16

MYX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mayne Pharma Group

Industry

Pharmaceuticals

Employees

450

CEO

Shawn Patrick O'Brien

Headquarters

Salisbury South, SA 5106, AU

MYX Financials

Key Financial Metrics (TTM)

Gross Margin

55%

Operating Margin

-11%

Net Income Margin

-20%

Return on Equity

-21%

Return on Capital

-7%

Return on Assets

-9%

Earnings Yield

-47.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$175.49M

Shares Outstanding

81.25M

Volume

324.63K

Short Interest

0.00%

Avg. Volume

545.67K

Financials (TTM)

Gross Profit

$247.27M

Operating Income

$23.59M

EBITDA

$42.08M

Operating Cash Flow

$17.47M

Capital Expenditure

$12.28M

Free Cash Flow

$5.19M

Cash & ST Invst.

$100.40M

Total Debt

$41.27M

Mayne Pharma Group Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$212.07M

+12.8%

Gross Profit

$106.80M

+43.7%

Gross Margin

50.36%

N/A

Market Cap

$175.49M

N/A

Market Cap/Employee

$206.46K

N/A

Employees

850

N/A

Net Income

$14.94M

+78.8%

EBITDA

$5.81M

+115.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$22.73M

-80.8%

Accounts Receivable

$192.59M

-3.2%

Inventory

$47.50M

-48.3%

Long Term Debt

$4.31M

-87.0%

Short Term Debt

$40.31M

+481.2%

Return on Assets

-8.85%

N/A

Return on Invested Capital

-6.65%

N/A

Free Cash Flow

$9.37M

+77.4%

Operating Cash Flow

$8.06M

+68.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCC.AXOrthocell Limited
$0.82-3.53%
DXB.AXDimerix Limited
$0.34-5.56%
MVF.AXMonash IVF Group Limited
$0.67+0.00%
BOT.AXBotanix Pharmaceuticals Limited
$0.04-2.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$48.96+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.45+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$67.86-0.02%
NOKNokia
$9.55+0.01%

Questions About MYX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.